Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revdofilimab + Tilsotolimod Combinations in R/M HNSCC
NCT04196283Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of revdofilimab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 2 years, Change in Vital Signs at 2 years and 6 more. Started Jan 2020; status: completed.
02
Drugs
revdofilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04196283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196283.